Susceptible genetic polymorphisms and their association with adverse effects of orlistat therapy

Orlistat is a tetrahydrolipstatin, which inhibits both pancreatic and gastric lipase enzymes in the gut prevents absorption of dietary fats intestine. Therefore, it widely used as an anti-obesity medication to control manage body weight obese patients worldwide. Despite this, mounting number clinical studies report that orlistat treatment induces adverse effects like pancreatitis, hepatic failure, kidney stone, acute oxalate nephropathy, others. Although various factors could mediate orlistat, emerging shreds evidence suggest genetic polymorphism-associated be primary reason for cause. Hence, this review, we first collated most critical caused by then appraised susceptible polymorphism further worsen orlistat. Nonetheless, review warrants similar conceptual approaches understand orlistat's selective improve therapeutic outcome